PSS35 - SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2535
https://www.valueinhealthjournal.com/article/S1098-3015(18)35837-6/fulltext
Title :
PSS35 - SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35837-6&doi=10.1016/j.jval.2018.09.2535
First page :
Section Title :
Open access? :
No
Section Order :
1885